Brought to you by 
Incyte acquires private pharmacogenetics firm Hexagen PLC
13 Jul 1999
Executive Summary
In an effort to build its pharmacogenetics business, Incyte Pharmaceuticals acquired Hexagen PLC (develops technology for discovery of single nucleotide polymorphisms (SNP)) and incorporated it into its newly formed Incyte Genetics unit.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Antisense, Oligonucleotides
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Incyte acquires private pharmacogenetics firm Hexagen PLC
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice